Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

BACKGROUND: The anti–human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody trastuzumab improves the outcome in patients with HER2-positive metastatic breast cancer. However, most cases of advanced disease eventually progress. Pertuzumab, an anti-HER2 humanized monoclonal anti...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:N Engl J Med
Autors principals: Baselga, José, Cortés, Javier, Kim, Sung-Bae, Im, Seock-Ah, Hegg, Roberto, Im, Young-Hyuck, Roman, Laslo, Pedrini, José Luiz, Pienkowski, Tadeusz, Knott, Adam, Clark, Emma, Benyunes, Mark C., Ross, Graham, Swain, Sandra M.
Format: Artigo
Idioma:Inglês
Publicat: 2011
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5705202/
https://ncbi.nlm.nih.gov/pubmed/22149875
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1113216
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars